High expression of EZH2 was most commonly observed in papillary SCC (5/5, 100%) (Figure 3D), non-keratinizing SCC (30/40, 75%) (Figure 1D), basaloid SCC (2/3, 66.6%) while low immunoexpression of EZH2 was predominantly found in keratinizing SCC (5/6, 83.3%) (Figure 1B) and in lymphoepithelioma-like carcinoma (1/1, 100%) (Table 2). Here, EZH2 is linked to carcinoma.